Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

The Multiple Myeloma Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Gold) and Legend Biotech (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.

Share this video  

IMW 2019 | Risk-adapted therapy in smoldering myeloma

Maria Victoria-Mateos • 12 Sep 2019
IMW 2019
Multiple Myeloma Rare Diseases Smoldering Myeloma Carfilzomib Daratumumab Dexamethasone Lenalidomide

In this video, Maria-Victoria Mateos, MD, PhD, from the University of Salamanca, Salamanca, Spain, expresses the importance of risk-adapted therapy in myeloma. This interview was recorded at the International Myeloma Workshop (IMW) 2019, held in Boston, MA.

More from Maria Victoria-Mateos

CANOVA trial: VenDex versus PomDex in patients with R/R multiple myeloma 1:53
CANOVA trial: VenDex versus PomDex in patients with R/R multiple myeloma
Maria Victoria-Mateos • 1 Jun 2024
Emerging therapies to address the unmet need for triple-class refractory multiple myeloma 2:17
Emerging therapies to address the unmet need for triple-class refractory multiple myeloma
Maria Victoria-Mateos • 1 Jun 2024
Findings from DREAMM-7 establish belantamab mafodotin as a new SoC for R/R multiple myeloma 2:16
Findings from DREAMM-7 establish belantamab mafodotin as a new SoC for R/R multiple myeloma
Maria Victoria-Mateos • 1 Jun 2024
Prophylactic tocilizumab to mitigate CRS: results from a small cohort in the MajesTEC-1 trial 1:46
Prophylactic tocilizumab to mitigate CRS: results from a small cohort in the MajesTEC-1 trial
Maria Victoria-Mateos • 1 Jun 2024

Related Videos

Belantamab mafodotin in functional high-risk RRMM: subgroup analysis of DREAMM-7 and DREAMM-8 4:02
Belantamab mafodotin in functional high-risk RRMM: subgroup analysis of DREAMM-7 and DREAMM-8
Meral Beksac • 10 Dec 2025
A real-world analysis of infections in patients with RRMM receiving ide-cel 3:59
A real-world analysis of infections in patients with RRMM receiving ide-cel
Muhammad Bilal Abid • 6 Dec 2025
Incidence and risk factors for infections in NDMM treated with modern induction regimens 1:54
Incidence and risk factors for infections in NDMM treated with modern induction regimens
Efstathios Kastritis • 7 Dec 2025
Integrating molecular diagnostics in smoldering myeloma to predict disease progression 1:37
Integrating molecular diagnostics in smoldering myeloma to predict disease progression
Gareth Morgan • 7 Dec 2025
The content of VJHemOnc is intended for healthcare professionals